article thumbnail

Checkpoint Inhibitors for Lung Cancer Linked to Pulmonary Embolism

Med Page Today

(MedPage Today) -- BOSTON -- Patients with metastatic lung cancer who were treated with immune checkpoint inhibitors (ICIs) had higher odds of developing a pulmonary embolism, according to a retrospective cohort study. Among propensity-matched.

Embolism 111
article thumbnail

Mechanisms and treatment of pulmonary arterial hypertension

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 07 August 2024; doi:10.1038/s41569-024-01064-4 In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical (..)

Pulmonary 124
article thumbnail

Dietary changes may treat pulmonary hypertension

Science Daily - Heart Disease

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic lung disease, heart failure and death.

Pulmonary 118
article thumbnail

Primary transcatheter dilation of the pulmonary valve in cyanotic patients with tetralogy of Fallot and dominant pulmonary valve stenosis

Frontiers in Cardiovascular Medicine

Differential growth of the pulmonary valve/annulus (PV) and arteries was documented, as was differential saturation improvement. ConclusionPalliative transcatheter dilation of predominantly pulmonary valve stenosis in patients with TOF and predominantly pulmonary valve stenosis is safe and effective in palliating cyanosis in most patients.

article thumbnail

SGLT2 Inhibitors Tied to Better Outcomes in Pulmonary Arterial Hypertension

Med Page Today

(MedPage Today) -- BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an observational cohort study.

Pulmonary 108
article thumbnail

Group clashes in pulmonary hypertension

Dr. S. Venkatesan MD

PH is an important clinical cardio-pulmonary entity , which we confront day to day. The group 1 contains the famous , (now obsolete entity of primary pulmonary hypertension) Idiopathic PH , meaning that we don’t know the cause of it or we have excluded all known causes. The overlaps in etiology 1.The

article thumbnail

Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension

Med Page Today

(MedPage Today) -- The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to increase exercise capacity.

Pulmonary 140